Please login to the form below

Not currently logged in
Email:
Password:

iBio and GE Healthcare extend Alliance into plant-based vaccines

Will use technology to make plants produce proteins

iBio and GE Healthcare have entered an alliance to commercialise plant-based technologies for the manufacture of biopharmaceuticals and vaccines, extending a collaboration originally formed in 2010.

The latest agreement involves the creation of a single facility with the ability to reduce the capital and operating costs of biotherapeutic and vaccine manufacture.

It combines GE Healthcare's technologies to manufacture biopharmaceuticals and other protein-based therapeutics, with iBio's own platform iBioLaunch.

This tool causes plants to rapidly produce high quantities of proteins that can then be used in vaccines.

It is based on gene expression technology, which can be scaled-up within low cost, controlled-growth facilities, according to iBio.

This provides potential to manufacture proteins that cannot be commercially produced in any other system.

The agreement will also see iBio's R&D collaborator, Fraunhofer US Center for Molecular Biotechnology (CMB) continue its involvement in the iBioLaunch platform.

Previous work involving the plant-technology includes an alliance between iBio and the Bill & Melinda Gates Foundation that has been used to produce an avian influenza vaccine candidate that successfully completed phase I clinical trials recently.

27th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
eyeforpharma

eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay...

Latest intelligence

How did pharma use Twitter at #ASCO16?
Each year, ASCO’s Annual Meeting brings together 30,000 oncology professionals from around the world, here we explore the #ASCO16 hashtag and how pharma utilised the channel during this year's event....
WHITE PAPER: How to engage with HCPs more effectively
Shrinking budgets and limitations on the time HCPs can spend with sales reps is making traditional engagement methods more and more ineffective. So, in order to reach the unreachable, pharma...
Evolve or die
How brand teams can bring more value to their customers...

Infographics